Teva: 'Hold' On FDA Approval Of Weltruza And Pivot To Growth Strategy

🌐 Seeking Alpha (United States) —

AI Summary

The headline indicates that Teva shares carry a Hold rating and discusses FDA approval of Weltruza alongside a growth-strategy pivot. The supplied description is blank, so further details about the regulatory decision or company plans are unavailable.

Markets Health Teva Weltruza FDA approval pharmaceuticals stock rating growth strategy

Read original source →